{"product_id":"legendbiotech-business-model-canvas","title":"Legend Biotech Business Model Canvas","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBiotech Business Model Canvas: Investor-ready roadmap for value creation and scalable growth\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eUnlock the full strategic blueprint behind Legend Biotech’s Business Model Canvas — a concise, actionable map of its value propositions, key partners, and revenue drivers. This professional, editable file is perfect for investors, strategists, and founders who need clear, company-specific insights. Purchase the full canvas to benchmark, plan, and scale with confidence.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eartnerships\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGlobal pharma co-development\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eStrategic alliances with large pharma expand clinical, regulatory, and commercial reach, as Legend’s 2017 collaboration with Janssen (USD 350 million upfront, up to ~USD 2 billion in milestones) provided global regulatory and commercialization scale. Co-development accelerates trials and label expansions while sharing risk and costs. Joint commercialization strengthens market access and post-launch evidence, and structured governance ensures aligned portfolio prioritization.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAcademic and clinical centers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003ePartnerships with leading cancer institutes enabled Legend Biotech’s clinical enrollment and translational research for cilta-cel, approved by the FDA in 2022, and continue to support ongoing registrational and post-marketing studies as of 2024. Access to KOLs refines protocols and endpoints, improving trial efficiency and regulatory dialogue. Real-world evidence generation strengthens payer health-economic cases, while shared biobanking accelerates biomarker discovery.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCDMOs and apheresis networks\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eCDMOs and apheresis networks extend Legend Biotech’s manufacturing footprint and patient reach, enabling production and collections across multiple geographies; as of 2024 Carvykti (cilta-cel) remains commercially distributed under this model. Standardized apheresis protocols improve starting material quality and reduce turnaround time for vein-to-vein workflows. Surge flexibility with contract partners mitigates demand spikes during launch or label expansions. Quality agreements enforce GMP and chain-of-identity controls across the supply chain.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRegulatory and HTA engagement\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eEarly scientific advice aligns Legend Biotech development with regulatory expectations; CARVYKTI received FDA approval in February 2022, anchoring ongoing dialogue. HTA bodies define evidence requirements for reimbursement and real-world evidence; payer-led managed entry agreements can de-risk adoption. Continuous regulator and HTA engagement speeds submissions and post-approval variations.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eRegulatory: FDA approval Feb 2022\u003c\/li\u003e\n\u003cli\u003eHTA: informs evidence for reimbursement\u003c\/li\u003e\n\u003cli\u003eManaged entry: de-risks payer uptake\u003c\/li\u003e\n\u003cli\u003eContinuous dialogue: accelerates filings\/variations\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTechnology and logistics providers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cpdigital vein-to-vein platforms enhance end-to-end tracking and scheduling targeting week turnaround cryogenic logistics specialists maintain vapor-phase ln2 conditions below to safeguard cell viability analytics partners drive capacity optimization yield improvements via real-time spc predictive maintenance cybersecure infrastructure enforces hipaa fda cfr part controls protect patient manufacturing data.\u003e\n\u003cp\u003e\u003c\/p\u003e\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eTracking: digital vein-to-vein platforms, 3–6 week TAT\u003c\/li\u003e\n\u003cli\u003eCold chain: vapor-phase LN2 \u0026lt; −130C\u003c\/li\u003e\n\u003cli\u003eAnalytics: real-time SPC, predictive maintenance\u003c\/li\u003e\n\u003cli\u003eSecurity: HIPAA and 21 CFR Part 11 compliance\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/pdigital\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eUSD 350M pharma deal and CDMO\/cold-chain partners underpin commercial CAR-T scale (FDA Feb 2022)\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eStrategic pharma alliances (Janssen deal: USD 350M upfront, up to ~USD 2B), academic\/clinical site networks, CDMO\/apheresis partners, regulator\/HTA engagement and digital cold-chain\/analytics partners underpin commercial CARVYKTI scale (FDA approval Feb 2022) and ongoing 2024 registrational\/post-marketing activity.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue (2024)\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eFDA approval\u003c\/td\u003e\n\u003ctd\u003eFeb 2022\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eJanssen deal\u003c\/td\u003e\n\u003ctd\u003eUSD 350M upfront; ~USD 2B milestones\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eVein-to-vein TAT\u003c\/td\u003e\n\u003ctd\u003e3–6 weeks\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCold chain\u003c\/td\u003e\n\u003ctd\u003eVapor-phase LN2 \u0026lt; −130C\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eA comprehensive Business Model Canvas for Legend Biotech detailing customer segments, channels, and value propositions across the 9 BMC blocks, reflecting its CAR‑T oncology platform, strategic partnerships, commercialization and R\u0026amp;D model, competitive advantages, risks and investor-ready insights for presentations and funding discussions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eHigh-level view of Legend Biotech’s business model with editable cells, enabling rapid alignment of R\u0026amp;D, commercialization and partnership strategies while saving hours on formatting.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eA\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003ectivities\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCell therapy R\u0026amp;D\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eDesign and optimization of CAR constructs and cell engineering methods drive Legend Biotech R\u0026amp;D, supporting ciltacabtagene autoleucel (Carvykti) commercialization after FDA approval in 2022. Rigorous preclinical efficacy and safety testing de-risks clinical entry and informs trial design. Platform innovations prioritize durability and safety while IP generation secures competitive positioning.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eClinical development\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eExecute multi-phase trials across hematologic and select solid tumors via the CARTITUDE program (CARTITUDE-1\/2\/3\/4), leveraging cilta-cel data showing a 97.9% overall response rate in CARTITUDE-1 and FDA approval on February 28, 2022. Expand labels through line extensions and earlier-line studies to broaden indications. Orchestrate global sites, centralized monitoring, and strict data-integrity systems. Patient-centric designs (decentralized visits, home nursing) improve enrollment and outcomes.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGMP manufacturing\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eScale GMP autologous processing with stringent QC\/QA to support commercial supply of cilta-cel (Carvykti), which has a U.S. list price of about 465,000 per treated patient, driving the need to improve yields and reduce per-patient cost. Optimize cycle time and release testing to shorten vein-to-vein timelines while implementing digital batch records and analytics for real-time deviation control. Validate additional sites and contract partners to add redundancy and capacity for global rollout.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRegulatory and market access\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003ePrepare regulatory submissions, respond to agency queries and meet post-approval commitments for cell therapy products (CARVYKTI received FDA approval in February 2022); build HTA value dossiers and economic models to support cost-effectiveness and budget impact; negotiate list prices, outcomes-based agreements and reimbursement pathways with payers; maintain global compliance and active pharmacovigilance for safety reporting.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eRegulatory filings: FDA approval Feb 2022\u003c\/li\u003e\n\u003cli\u003eHTA focus: value dossiers \u0026amp; economic models\u003c\/li\u003e\n\u003cli\u003eCommercial: pricing, outcomes-based contracts\u003c\/li\u003e\n\u003cli\u003eCompliance: global pharmacovigilance \u0026amp; post-market commitments\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCommercialization and medical affairs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eCommercialization and medical affairs educate HCPs and referral centers on patient selection and management, coordinate patient services and case management, generate real-world evidence to support uptake and reimbursement, and provide center training, logistics and quality programs; activity intensified following FDA approval in 2022 and global rollout with commercial partners through 2024.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eEducate HCPs\/centers on referral and management\u003c\/li\u003e\n\u003cli\u003eCoordinate patient services \u0026amp; case management\u003c\/li\u003e\n\u003cli\u003eGenerate \u0026amp; disseminate real-world evidence\u003c\/li\u003e\n\u003cli\u003eSupport training, logistics \u0026amp; quality programs\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eScale CAR-T autologous manufacturing, preserve CARTITUDE-1 safety\/efficacy (ORR \u003cstrong\u003e97.9%\u003c\/strong\u003e)\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eDesign and optimize CAR constructs and GMP autologous manufacturing to commercialize cilta-cel (FDA approved Feb 28, 2022), maintain safety\/efficacy via preclinical and CARTITUDE trials (CARTITUDE-1 ORR 97.9%), and execute global regulatory, payer negotiations and post-market pharmacovigilance.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eFDA approval\u003c\/td\u003e\n\u003ctd\u003eFeb 28, 2022\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCARTITUDE-1 ORR\u003c\/td\u003e\n\u003ctd\u003e97.9%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eUS list price\u003c\/td\u003e\n\u003ctd\u003e~465,000 per patient\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eDelivered as Displayed\u003c\/span\u003e\u003cbr\u003e Business Model Canvas\u003c\/h2\u003e\n\u003cp\u003eThe Business Model Canvas you’re previewing for Legend Biotech is the actual deliverable, not a mockup or sample. When you purchase, you’ll receive this exact document—complete, fully formatted, and ready to edit. No surprises: what you see is what you’ll download and use.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"PortersFiveForce","offers":[{"title":"Default Title","offer_id":56161507967353,"sku":"legendbiotech-business-model-canvas","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0914\/5276\/8633\/files\/legendbiotech-business-model-canvas.png?v=1762694180","url":"https:\/\/portersfiveforce.com\/products\/legendbiotech-business-model-canvas","provider":"Porter's Five Forces","version":"1.0","type":"link"}